Nutra Pharmaceutical's U.S. distributor, XenaCare Holdings announced that its national print advertising campaign for Cobroxin, the first clinically proven, over-the-counter treatment for moderate to severe (stage 2) chronic pain, is scheduled to begin in November and will run in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self Magazines.
(Vocus) September 4, 2009 -- Cobroxin, which was developed by Nutra Pharma Corporation (OTCBB: NPHC), is the first opiate and acetaminophen-free pain reliever available as an over-the-counter formulation that is clinically proven to treat moderate to severe (Stage 2) chronic pain. In August, Nutra Pharma granted XenaCare Holdings the exclusive license for marketing and distributing Cobroxin throughout the United States.
XenaCare Holdings, Inc. (OTCBB: XCHO), a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that it will begin its national print advertising campaign for Cobroxin in November. The campaign, which is budgeted at approximately $550,000, is scheduled to run through December and will appear in Arthritis Today, Prevention, Health, Star, Woman's World, Soap Opera, and Self magazines.
“This advertising campaign represents the first of several national campaigns we plan to roll out as we introduce Cobroxin through national retailers in the coming months,” explained Frank Rizzo, President of XenaCare Holdings, Inc. “In addition to print advertising, we are also finalizing online marketing campaigns and television commercials,” he concluded.
Copyright©2009 Vocus, Inc.
All rights reserved